C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress

Trends in Molecular Medicine

Volumn 15, Issue 2, 2009, Pages 69-78

  Cugno, Massimo ^a   Zanichelli, Andrea ^b   Foieni, Fabrizio ^b   Caccia, Sonia ^a   Cicardi, Marco ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANDROGEN; ANTIFIBRINOLYTIC AGENT; BRADYKININ; BRADYKININ RECEPTOR; CINRYZE; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; ECALLANTIDE; FIRAZYR; FRESH FROZEN PLASMA; ICATIBANT; KININ; METHYLTESTOSTERONE; PLACEBO; RHUCIN; STANOZOLOL; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BLOOD VESSEL PERMEABILITY; CAUSAL ATTRIBUTION; CLINICAL TRIAL; COMPLEMENT DEFICIENCY; COMPLEMENT SYSTEM; CRYSTAL STRUCTURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG COST; DRUG MECHANISM; FLUSHING; FOOD AND DRUG ADMINISTRATION; GENE INTERACTION; GENE MUTATION; HOMEOSTASIS; HUMAN; INJECTION SITE DISCOMFORT; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; RHINITIS; SIDE EFFECT; SIGNAL TRANSDUCTION;

ANGIOEDEMA; BRADYKININ; CAPILLARY PERMEABILITY; COMPLEMENT C1 INHIBITOR PROTEIN; HOMEOSTASIS; HUMANS; KALLIKREINS; MODELS, MOLECULAR; PEPTIDE HYDROLASES; PROTEIN STRUCTURE, TERTIARY;

ANIMALIA;

EID: 60949104520     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2008.12.001     Document Type: Review

References (94)

1. Silverman G.A., et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem. 276 (2001) 33293-33296
2. Davis A.E., 3rd, et al. C1 inhibitor: biologic activities that are independent of protease inhibition. Immunobiology 212 (2007) 313-323
3. Bergamaschini L., and Cicardi M. Recent advances in the use of C1 inhibitor as a therapeutic agent. Mol. Immunol. 40 (2003) 155-158
4. Ennis S., et al. Association between the SERPING1 gene and age-related macular degeneration: a two-stage case-control study. Lancet 372 (2008) 1828-1834
5. Pappalardo E., et al. Mechanisms of C1-inhibitor deficiency. Immunobiology 205 (2002) 542-551
6. Patston P.A., et al. Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate. Biochemistry 30 (1991) 8876-8882
7. Gettins P.G. Serpin structure, mechanism, and function. Chem. Rev. 102 (2002) 4751-4804
8. Huntington J.A., et al. Structure of a serpin-protease complex shows inhibition by deformation. Nature 407 (2000) 923-926
9. Beinrohr L., et al. C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease. J. Biol. Chem. 282 (2007) 21100-21109
10. Kalmar L., et al. HAEdb: a novel interactive, locus-specific mutation database for the C1 inhibitor gene. Hum. Mutat. 25 (2005) 1-5
11. Pappalardo E., et al. Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates. Mol. Immunol. 45 (2008) 3536-3544
12. Davies M.J., and Lomas D.A. The molecular aetiology of the serpinopathies. Int. J. Biochem. Cell Biol. 40 (2008) 1273-1286
13. Lomas D.A., et al. Molecular mousetraps and the serpinopathies. Biochem. Soc. Trans. 33 (2005) 321-330
14. Lomas D.A., and Carrell R.W. Serpinopathies and the conformational dementias. Nat. Rev. Genet. 3 (2002) 759-768
15. Carrell R.W., and Lomas D.A. Alpha1-antitrypsin deficiency - a model for conformational diseases. N. Engl. J. Med. 346 (2002) 45-53
16. Yamasaki M., et al. Crystal structure of a stable dimer reveals the molecular basis of serpin polymerization. Nature 455 (2008) 1255-1258
17. Whisstock J.C., and Bottomley S.P. Structural biology: Serpins' mystery solved. Nature 455 (2008) 1189-1190
18. Eldering E., et al. COOH-terminal substitutions in the serpin C1 inhibitor that cause loop overinsertion and subsequent multimerization. J. Biol. Chem. 270 (1995) 2579-2587
19. Aulak K.S., et al. A hinge region mutation in C1-inhibitor (Ala436→Thr) results in nonsubstrate-like behavior and in polymerization of the molecule. J. Biol. Chem. 268 (1993) 18088-18094
20. Quastel M., et al. Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J. Clin. Invest. 71 (1983) 1041-1046
21. Cugno M., et al. Plasma levels of C1- inhibitor complexes and cleaved C1- inhibitor in patients with hereditary angioneurotic edema. J. Clin. Invest. 85 (1990) 1215-1220
22. Pappalardo E., et al. C1 inhibitor gene expression in patients with hereditary angioedema: quantitative evaluation by means of real-time RT-PCR. J. Allergy Clin. Immunol. 114 (2004) 638-644
23. Caldwell J.R., et al. Acquired C1 inhibitor deficiency in lymphosarcoma. Clin. Immunol. Immunopathol. 1 (1972) 39-52
24. Zingale L.C., et al. Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management. Immunol. Allergy Clin. North Am. 26 (2006) 669-690
25. Geha R.S., et al. Acquired C1-inhibitor deficiency associated with antiidiotypic antibody to monoclonal immunoglobulins. N. Engl. J. Med. 312 (1985) 534-540
26. Jackson J., et al. An IgG autoantibody which inactivates C1-inhibitor. Nature 323 (1986) 722-724
27. Chatila T.A. Role of regulatory T cells in human diseases. J. Allergy Clin. Immunol. 116 (2005) 949-959
28. Cicardi M., et al. Relevance of lymphoproliferative disorders and of anti-C1 inhibitor autoantibodies in acquired angio-oedema. Clin. Exp. Immunol. 106 (1996) 475-480
29. Smedby K.E., et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J. Natl. Cancer Inst. 98 (2006) 51-60
30. Castelli R., et al. Lymphoproliferative disease and acquired C1 inhibitor deficiency. Haematologica 92 (2007) 716-718
31. Bhoola K.D., et al. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 44 (1992) 1-80
32. Cugno M., et al. Bradykinin in the ascitic fluid of patients with liver cirrhosis. Clin. Sci. 101 (2001) 651-657
33. Kaplan A.P., et al. Pathways for bradykinin formation and inflammatory disease. J. Allergy Clin. Immunol. 109 (2002) 195-209
34. Schmaier A.H., and McCrae K.R. The plasma kallikrein-kinin system: its evolution from contact activation. J. Thromb. Haemost. 5 (2007) 2323-2329
35. Schmaier A.H. The elusive physiologic role of Factor XII. J. Clin. Invest. 118 (2008) 3006-3009
36. Shariat-Madar Z. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J. Biol. Chem. 277 (2002) 17962-17969
37. Joseph K., et al. Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 896-900
38. Schmaier A.H. Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system. Int. Immunopharmacol. 8 (2008) 161-165
39. Leeb-Lundberg L.M., et al. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. 57 (2005) 27-77
40. Davis III A.E. Hereditary angioedema: a current state-of-the-art review. III: mechanisms of hereditary angioedema. Ann. Allergy Asthma Immunol. 100 (2008) S7-S12
41. Cugno M., et al. Bradykinin and the pathophysiology of angioedema. Int. Immunopharmacol. 3 (2003) 311-317
42. Han E.D., et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J. Clin. Invest. 109 (2002) 1057-1063
43. Bork K., et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J. Allergy Clin. Immunol. 119 (2007) 1497-1503
44. Joseph K., et al. Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma. Ann. Allergy Asthma Immunol. 101 (2008) 279-286
45. Nussberger J., et al. Plasma bradykinin in angio-oedema. Lancet 351 (1998) 1693-1697
46. Cugno M., et al. Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of tranexamic acid. J. Allergy Clin. Immunol. 93 (1994) 870-876
47. Nussberger J., et al. Bradykinin-mediated angioedema. N. Engl. J. Med. 347 (2002) 621-622
48. Cugno M., et al. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 89 (1997) 3213-3218
49. Nussberger J., et al. Local bradykinin generation in hereditary angioedema. J. Allergy Clin. Immunol. 104 (1999) 1321-1322
50. Agostoni A., et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J. Allergy Clin. Immunol. 114 (2004) S51-S131
51. Spaulding W.B. Methyltestosterone therapy for hereditary episodic edema (hereditary angioneurotic edema). Ann. Intern. Med. 53 (1960) 739-745
52. Donaldson V.H., et al. Permeability-increasing activity in hereditary angioneurotic edema plasma. II. Mechanism of formation and partial characterization. J. Clin. Invest. 48 (1969) 642-653
53. Banerji A., et al. Hereditary angioedema: a current state-of-the-art review, V: attenuated androgens for the treatment of hereditary angioedema. Ann. Allergy Asthma Immunol. 100 (2008) S19-S22
54. Gelfand J.A., et al. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N. Engl. J. Med. 295 (1976) 1444-1448
55. Pappalardo E., et al. Increased expression of C1-inhibitor mRNA in patients with hereditary angioedema treated with Danazol. Immunol. Lett. 86 (2003) 271-276
56. Drouet C., et al. Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. J. Allergy Clin. Immunol. 121 (2008) 429-433
57. Pickering R.J., et al. Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma. Lancet 1 (1969) 326-330
58. Hill B.J., et al. Fresh frozen plasma for acute exacerbations of hereditary angioedema. Am. J. Emerg. Med. 22 (2004) 633
59. Cicardi M., et al. The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema. Expert Opin. Pharmacother. 8 (2007) 3173-3181
60. Kunschak M., et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 38 (1998) 540-549
61. Waytes A.T., et al. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N. Engl. J. Med. 334 (1996) 1630-1634
62. Agostoni A., and Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 71 (1992) 206-215
63. Bork K., et al. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 45 (2005) 1774-1784
64. Bork K., and Barnstedt S.E. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch. Intern. Med. 161 (2001) 714-718
65. Bowen T., et al. Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann. Allergy Asthma Immunol. 100 1 Suppl. 2 (2008) S30-S40
66. Gompels M.M., et al. C1 inhibitor deficiency: consensus document. Clin. Exp. Immunol. 139 (2005) 379-394
67. Bowen T., et al. Management of hereditary angioedema: a Canadian approach. Transfus. Apheresis Sci. 29 (2003) 205-214
68. Longhurst H.J., et al. C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option. Clin. Exp. Immunol. 147 (2007) 11-17
69. Levi M., et al. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J. Allergy Clin. Immunol. 117 (2006) 904-908
70. Marasini B., et al. Treatment of hereditary angioedema. Klin. Wochenschr. 56 (1978) 819-823
71. Vogelaar E.F., et al. Contributions to the optimal use of human blood. 3. Large-scale preparation of human c1 esterase inhibitor concentrate for clinical use. Vox Sang. 26 (1974) 118-127
72. Terpstra F.G., et al. Viral safety of C1-inhibitor NF. Biologicals 35 (2007) 173-181
73. Zuraw B., et al. Efficacy and safety of long-term prophylaxis with C1 inhibitor (C1INH) concentrate in patients with hereditary angioedema (HAE). J. Allergy Clin. Immunol. 121 (2008) S272
74. Bernstein J.A., et al. Treatment of acute abdominal and facial attacks of hereditary angioedema (HAE) with human C1 esterase inhibitor (C1-INH): results of a global, multicenter, randomized, placebo-controlled, Phase II/III Study (I.M.P.A.C.T.1). J. Allergy Clin. Immunol. 121 (2008) 795
75. Choi G., et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion 47 (2007) 1028-1032
76. Cicardi M., et al. A randomised, placebo-controlled, double blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema. Mol. Immunol. 45 (2008) 4118-4119
77. Williams A., and Baird L.G. DX-88 and HAE: a developmental perspective. Transfus. Apheresis Sci. 29 (2003) 255-258
78. Cicardi M., et al. Hereditary angioedema: an appraisal of 104 cases. Am. J. Med. Sci. 284 (1982) 2-9
79. Gonzales-Quevedo T., et al. The synthetic Kunitz domain protein Dx88 to treat angioedema in patients with hereditary angioedema. Int. Immunopharmacol. 2 (2002) 1318
80. Schneider L., et al. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J. Allergy Clin. Immunol. 120 (2007) 416-422
81. Lumry W., et al. Interim results of EDEMA2, a multicenter, open-label, repeat-dosing study of intravenous and subcutaneous administration of ecallantide (DX-88) in hereditary angioedema. J. Allergy Clin. Immunol. 117 (2006) S179
82. Williams T. DX-88, a novel recombinant protein inhibitor of plasma kallikrein: safety and immunogenicity in early studies. J. Allergy Clin. Immunol. 115 (2005) S181
83. Caballero T., and Lopez-Serrano C. Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema. J. Allergy Clin. Immunol. 117 (2006) 476-477
84. [No authors listed] (2004) Icatibant: HOE 140, JE 049, JE049. Drugs R D. 5, 343-348
85. Bas M., et al. Novel pharmacotherapy of acute hereditary angioedema with bradykinin B2-receptor antagonist icatibant. Allergy 61 (2006) 1490-1492
86. Levi M., et al. Rituximab-induced elimination of acquired angioedema due to C1-inhibitor deficiency. Am. J. Med. 119 (2006) e3-e5
87. Sanchez-Cano D., et al. Successful use of rituximab in acquired C1 inhibitor deficiency secondary to Sjogren's syndrome. Lupus 17 (2008) 228-229
88. Lehmann A. Ecallantide (Dyax/Genzyme). Curr. Opin. Investig. Drugs 7 (2006) 282-290
89. Sheffer A.L., et al. Tranexamic acid therapy in hereditary angioneurotic edema. N. Engl. J. Med. 287 (1972) 452-454
90. Blohme G., et al. Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study. Acta Med. Scand. 192 (1972) 293-298
91. Frank M.M., et al. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N. Engl. J. Med. 286 (1972) 808-812
92. Dullweber F., et al. Factorising ligand affinity: a combined thermodynamic and crystallographic study of trypsin and thrombin inhibition. J. Mol. Biol. 313 (2001) 593-614
93. Dementiev A., et al. Canonical inhibitor-like interactions explain reactivity of α1-proteinase inhibitor Pittsburgh and antithrombin with proteinases. J. Biol. Chem. 278 (2003) 37881-37887
94. Moy F.J., et al. NMR structure of free RGS4 reveals an induced conformational change upon binding Gα. Biochemistry 39 (2000) 7063-7073